Particle-Enhanced Turbidimetric Immunoassay Market Worth Is Likely To Grow At 4.3% By 2031

Between 2021 and 2031, the market for particle-enhanced turbidimetric immunoassays (PETIA) is anticipated to increase rapidly. Some of the key elements propelling the market for particle-enhanced turbidimetric immunoassays are the rising incidence of infectious disorders and the expanding interest in medical research.

Recently, medical professionals and researchers have become very interested in PETIA. This method provides a number of benefits. It is perfect for quantitative measurements of proteins, pathogens, and other compounds in bodily fluids including urine, plasma, and serum because of how quickly and affordably it can be done.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.factmr.com/connectus/sample?flag=S&rep_id=6899?PS

Due to the quick and reliable antibody-antigen interaction that occurs during PETIA, it has been frequently employed in clinical diagnostics to quantify hundreds of circulating proteins. Ready-to-use PETIA kits have been created by a number of medical organisations and businesses, including ImmunoDiagnostics Limited (IMD), to aid in the risk assessment and diagnosis of chronic diseases.

Increasing funding by government and other healthcare organization will expand the PETIA market during the forecast period. As per Fact.MR, the hospital segment is poised to emerge as the leading end user for PETIA products during the forecast period.

North America leads the PETIA market as a result of increasing prevalence of infectious diseases, presence of leading players, and recent advances in the medical research.

"Particle-enhanced turbidimetric immunoassays' flexibility make it ideal for integration with chemical analyzers in laboratory infrastructure. The technique is therefore increasingly used to get desired reading within a couple of minutes from its initiation, thus increasing the number of samples analyzed on a daily basis," says the Fact.MR analyst.

𝐊𝐞𝐲 𝐓𝐚𝐤𝐞𝐚𝐰𝐚𝐲𝐬 𝐟𝐫𝐨𝐦 𝐏𝐚𝐫𝐭𝐢𝐜𝐥𝐞-𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐓𝐮𝐫𝐛𝐢𝐝𝐢𝐦𝐞𝐭𝐫𝐢𝐜 𝐈𝐦𝐦𝐮𝐧𝐨𝐚𝐬𝐬𝐚𝐲𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐮𝐫𝐯𝐞𝐲

With high prevalence of infectious diseases and presence of advanced healthcare and research setups, North America dominates the PETIA market.
The U.S. is emerging as the most lucrative market for PETIA. The robust growth in the country can be attributed to the presence of leading market players and international medical research organizations.

The Europe market is poised to exhibit high demand as research initiatives for novel drug discovery pick up pace in the U.K. and Germany.
Diagnosis of infectious disease remains the leading application for PETIA technique.
Hospitals are expected to emerge as the leading end user for PETIA during the forecast period.

𝐊𝐞𝐲 𝐃𝐫𝐢𝐯𝐞𝐫𝐬

• Increasing prevalence of various diseases is mainly driving the PETIA market.
• Advances in medical research is positively impacting the market growth.
• Low cost and shorter time-to-result of PETIA makes it more preferred as compared to its counterparts.
• Rising geriatric population is expected to create huge demand for PETIA during the forecast period.
• COVID-19 pandemic supported the market growth as various companies started to develop testing kits using PETIA technology.

𝐊𝐞𝐲 𝐑𝐞𝐬𝐭𝐫𝐚𝐢𝐧𝐭𝐬

Lack of awareness about this novel technique across developing and underdeveloped countries is hampering the growth of PETIA market.
Low penetration of PETIA products also impacts the market growth.

𝐂𝐨𝐦𝐩𝐞𝐭𝐢𝐭𝐢𝐯𝐞 𝐋𝐚𝐧𝐝𝐬𝐜𝐚𝐩𝐞

Key players operating in the PETIA market are focusing on developing novel products using PETIA technique. They have developed various strategies such as advanced product launch, mergers and acquisitions to stay relevant in the market and expand their presence.

In August 2020, Gentian Diagnostics ASA added the Gentian Calprotectin Immunoassay (GCAL), the first turbidimetric assay for the quantitative measurement of calprotectin in plasma and serum intended as an aid in the detection and assessment of inflammation, to its catalogue.
In August 2020, TRIMERO Dianostics added new Serum Amyloid A, CE-IVD marked, particle-enhanced turbidimetric immunoassay to its catalogue.

In August 2020, Genetian Diagnostics ASA announced that it will launch COVID-19 antibody test using its unique PETIA technology. The Genetian antibody test will be a turbidimetric COVID-19 assay using the PETIA technology.

𝐒𝐨𝐦𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐩𝐫𝐨𝐦𝐢𝐧𝐞𝐧𝐭 𝐦𝐚𝐧𝐮𝐟𝐚𝐜𝐭𝐮𝐫𝐞𝐫𝐬 𝐚𝐧𝐝 𝐬𝐮𝐩𝐩𝐥𝐢𝐞𝐫𝐬 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞-𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐭𝐮𝐫𝐛𝐢𝐝𝐢𝐦𝐞𝐭𝐫𝐢𝐜 𝐢𝐦𝐦𝐮𝐧𝐨𝐚𝐬𝐬𝐚𝐲𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐩𝐫𝐨𝐟𝐢𝐥𝐞𝐝 𝐛𝐲 𝐅𝐚𝐜𝐭.𝐌𝐑 𝐚𝐫𝐞:

Gentian Diagnostics ASA
Eurospital
Calpro
Thermo-Fisher Scientific
Buehlmann
Biotec
Abbott Laboratories
F.Hoffmann-La Roche
Siemens AG
Danaher Corporation
Diasorin SPA
Sysmex Corporation
Biomerieux SA
QIAGEN
Agilent Technologies, Inc

A PETIA prototype that can measure the amounts of calprotectin in serum or plasma was created by researchers at Uppsala University in Norway. Since calprotectin is referred to as the body's inflammation marker, this technology can be utilised to measure its levels in inflammatory bowel problems. Such novel approaches to already-available technologies are what will steer the market in a lucrative path.

𝐆𝐞𝐭 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐭𝐡𝐢𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=6899?PS

𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐨𝐧 𝐭𝐡𝐞 𝐆𝐥𝐨𝐛𝐚𝐥 𝐏𝐚𝐫𝐭𝐢𝐜𝐥𝐞-𝐄𝐧𝐡𝐚𝐧𝐜𝐞𝐝 𝐓𝐮𝐫𝐛𝐢𝐝𝐢𝐦𝐞𝐭𝐫𝐢𝐜 𝐈𝐦𝐦𝐮𝐧𝐨𝐚𝐬𝐬𝐚𝐲𝐬 𝐒𝐚𝐥𝐞𝐬 𝐎𝐮𝐭𝐥𝐨𝐨𝐤

Fact.MR provides an unbiased analysis of particle-enhanced turbidimetric immunoassays market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global demand PETIA with a detailed segmentation on the basis of:

Application:

Infectious Diseases
Endocrinology
Cardiology
Oncology
Bone and Mineral Diseases
Autoimmune Disorders
Others

End User:

Hospitals
Academic and Research Institutions
Pharmaceutical and Biotechnology Companies
Others

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

Contact:

Us Sales Office :
11140 Rockville Pike
Suite 400
Rockville, Md 20852
United States
Tel: +1 (628) 251-1583

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range - from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories.

This release was published on openPR.